Actively Recruiting
Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
Led by Peking University Cancer Hospital & Institute · Updated on 2024-11-25
20
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the ability of [68Ga]N188, a radiolabelled probe targeting nectin-4, to detect overexpression of nectin-4 in patients with various lung lesions, including inflammation and lung cancer. This observational study aims to improve diagnostic imaging for these conditions by assessing the probe's uptake in affected lung tissue. Participants will undergo PET/CT imaging using the [68Ga]N188 probe to identify nectin-4 expression. Additionally, all participants will have an 18F-FDG PET/CT scan within one week as part of the study procedures. The study includes adults between 18 and 75 years old and includes measures to ensure participant safety and compliance. During the study, participants will be assessed through imaging scans and clinical follow-up to measure the standardized uptake value (SUV) of the probe over one year. Researchers will monitor heart function and other health parameters to ensure safety. Participants are expected to comply with follow-up visits and may undergo pregnancy testing and contraception use if applicable. The total study period includes initial imaging and long-term observation of imaging outcomes.
CONDITIONS
Brief Title
Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years, male or female
- Normal heart function
- Estimated survival of at least 12 weeks
- Good compliance with follow-up visits
- At least one measurable target lung lesion according to RECIST1.1 criteria
- Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting
- Fertile men and women must agree to use effective contraception during the study and for 3 months after
- Patients recommended by clinicians for PET/CT for tumor diagnostic staging
- Ability to understand and voluntarily consent to participate
You will not qualify if you...
- Serious abnormalities of liver, kidney, or blood function
- Pregnant or breastfeeding women
- Unable to lie flat for half an hour
- Refusal to participate in the clinical trial
- Claustrophobia or other mental health conditions
- Any other condition deemed unsuitable by the researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within 1 week
Participants undergo PET/CT scans to evaluate lung lesions and detect nectin-4 overexpression.
1 visit (in-person)
Duration - 1 year
Participants are monitored for changes in standardized uptake value (SUV) over 1 year.
Follow-up visits as scheduled for up to 1 year
Trial Site Locations
Total: 1 location
1
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
N
Nan Li
X
Xin Zhou, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here